HDFC MF and ADIA Lead Major ₹777 Crore Block Deal in Corona Remedies
A massive liquidity event unfolded in the pharmaceutical sector as Sepia Investments and Anchor Partners offloaded significant stakes in Corona Remedies Limited. This high-value block deal attracted a heavy-weight lineup of domestic and international institutional investors, signaling strong confidence in the company's long-term prospects.
Breakdown of the Mega Divestment
On June 17, 2026, the stock exchange witnessed a substantial transfer of ownership in Corona Remedies. The primary seller, Sepia Investments, divested 43,28,943 shares at a price of ₹1,730 per share, amounting to approximately ₹748.9 crore.
Adding to this exit, Anchor Partners also offloaded 1,61,861 shares at the same price point of ₹1,730, contributing an additional ₹28 crore to the transaction. In total, these two sellers collectively exited positions worth roughly ₹776.9 crore in the pharmaceutical major.
HDFC Mutual Fund Dominates the Buy Side
The transaction saw participation from twelve distinct institutional buyers, with HDFC Mutual Fund emerging as the most aggressive acquirer. By purchasing 24,50,000 shares, HDFC MF invested approximately ₹423.9 crore, effectively absorbing more than half of the total deal value.
The buy-side appetite was further bolstered by several other major players:
- Aditya Birla Sun Life Mutual Fund: Acquired 4,90,000 shares worth ₹84.8 crore.
- Aberdeen Asian Smaller Companies Investment Trust Plc: Bought 4,50,868 shares for roughly ₹78 crore.
- Invesco Mutual Fund: Picked up 2,89,017 shares valued at ₹50 crore.
- Aberdeen Standard Sicav I: Acquired 2,74,132 shares worth ₹47.4 crore.
Global Institutional Interest in Corona Remedies
Beyond domestic mutual funds, the deal highlighted significant interest from global sovereign wealth and international asset management firms. The Abu Dhabi Investment Authority (ADIA) participated in the deal, acquiring 39,130 shares worth approximately ₹6.8 crore.
다른 주목할 만한 해외 참여자로는 2억 5,100만 루피(₹25.1 crore)를 투자한 WhiteOak Capital Mutual Fund와 2억 5,700만 루피(₹25.7 crore)를 투자한 India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund가 있습니다. 또한 Kotak Mahindra Mutual Fund(2억 8,000만 루피), Factory Mutual Insurance Company(1,900만 루피), TCW White Oak Emerging Markets Equity Fund(330만 루피)의 소규모 참여도 있었으며, 이는 해당 주식의 가치 평가에 대한 기관들의 폭넓은 합의를 보여줍니다.
핵심 요약
- 대규모 유동성 이벤트: Sepia Investments와 Anchor Partners의 총 매각 규모는 주당 1,730 루피 가격으로 약 776억 9,000만 루피(₹776.9 crore)에 달했습니다.
- HDFC MF의 압도적인 비중: HDFC Mutual Fund는 423억 9,000만 루피(₹423.9 crore)를 투자하며 거래 가치의 50% 이상을 차지하는 핵심 투자자(cornerstone buyer) 역할을 했습니다.
- 다양한 투자자 기반: 이번 거래에는 인도의 국내 뮤추얼 펀드와 ADIA, Aberdeen 같은 글로벌 대형 기관들이 조화롭게 참여하였으며, 이는 Corona Remedies에 대한 기관들의 강력한 신뢰를 나타냅니다.